Anton Gulevich is an accomplished medicinal chemist with extensive experience in oncology and drug discovery. Currently serving as a Sr. Scientific Lead and Scientific Director at Eli Lilly and Company since December 2022, Gulevich supports antibody-drug conjugate projects and leads chemistry efforts for kinase inhibitor initiatives. Prior experience includes a role as Principal Scientist in Medicinal Chemistry at Loxo@Lilly, focused on covalent kinase inhibitors and targeted protein degradation, as well as significant contributions at Vertex Pharmaceuticals, where leadership in the discovery of NaV 1.8 inhibitor VX-993 was achieved. Academic training includes a Postgraduate Degree in Organic Chemistry from the University of Illinois Chicago and a PhD from Lomonosov Moscow State University, complemented by postdoctoral research that produced innovative metal-catalyzed transformations and a strong publication record.
This person is not in any teams
This person is not in any offices